REG - Hutchmed China Ltd - Block Admission Application

HUTCHMED (China)Announcement

05/06/2026 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260605:nRSE0348Ha&default-theme=true

RNS Number : 0348H  Hutchmed (China) Limited  05 June 2026

Block Admission Application

Hong Kong, Shanghai & Florham Park, NJ - Friday, June 5, 2026: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM: HCM; SEHK:13) today announces an application has been made to the
London Stock Exchange plc for a block admission of 43,616,756 ordinary shares,
par value of US$0.10 each ("Ordinary Shares") to be admitted to trading on
AIM.  It is expected that such admission will become effective on June 11,
2026.

 

These Ordinary Shares will be issued from time to time pursuant to the
exercise of share options under the Share Option Scheme adopted by the Company
in 2026 ("2026 Share Option Scheme").  When issued, these Ordinary Shares
will be credited as fully paid and will rank pari passu with the existing
Ordinary Shares in issue. The Company is seeking this block admission due to
the adoption of the 2026 Share Option Scheme, as approved at its annual
general meeting held on May 12, 2026 ("AGM"), whereby the Company was
empowered to grant options under that scheme in respect of a maximum of
43,616,756 Ordinary Shares. Following admission, the total issued share
capital of the Company remains unchanged at 872,335,120 Ordinary Shares, with
each share carrying one right to vote and with no shares held in treasury.
The Company will make six-monthly announcements of the utilisation of the
block admission, in line with its obligations under AIM Rule 29 and monthly
announcements as to any changes to its total voting rights.

 

The balance of the existing block admission in respect of the Company's
previous share option scheme adopted in 2015 of 45,768,368 Ordinary Shares
(the "Existing Block Admission") remains in effect.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of
the "safe harbor" provisions of the US Private Securities Litigation Reform
Act of 1995. Forward-looking statements involve risks and uncertainties.
Existing and prospective investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see HUTCHMED's filings with
the US Securities and Exchange Commission, The Stock Exchange of Hong Kong
Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the
information contained in this announcement, whether as a result of new
information, future events or circumstances or otherwise.

 

CONTACTS
 Investor Enquiries                             +852 2121 8200 / ir@hutch-med.com

 Media Enquiries
 FTI Consulting -                               +44 20 3727 1030 / HUTCHMED@fticonsulting.com
    Ben Atwell / Tim Stamper                       +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
 Brunswick - Zhou Yi                            +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

 Panmure Liberum                                Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden    +44 20 7886 2500

 Cavendish                                      Joint Broker
 Geoff Nash / Nigel Birks                       +44 20 7220 0500

 Deutsche Numis                                 Joint Broker
 Duncan Monteith / Ramin Naji                   +44 20 7545 8000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ADMBGGDLUBGDGLS



            Copyright 2019 Regulatory News Service, all rights reserved